Travere Therapeutics, Inc.
TVTXTravere Therapeutics is a biopharmaceutical company dedicated to the development and commercialization of therapies for rare kidney and metabolic diseases.
Earnings
Next report
Nov 2, 2026 (Today)Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
Travere Therapeutics is a biopharmaceutical company dedicated to the development and commercialization of therapies for rare kidney and metabolic diseases. The company focuses on addressing significant unmet medical needs through a pipeline of late-stage clinical programs and commercialized products. Its core value proposition lies in delivering disease-modifying treatments that slow disease progression and improve long-term outcomes for patients with life-threatening rare conditions.
A leading innovator in the rare kidney disease space with the first FDA-approved non-immunosuppressant therapy for IgAN.
FAQ
- What is Travere Therapeutics, Inc.'s market cap?
- Travere Therapeutics, Inc. (TVTX) has a market capitalization of $4.8B and trades on NASDAQ.
- What is Travere Therapeutics, Inc.'s revenue and profitability?
- Travere Therapeutics, Inc. generated $591.3M in trailing twelve-month revenue, representing a net margin of -20.3%. Gross margin stands at 98.6%. The latest reported period is Q2 2026.
- Who are Travere Therapeutics, Inc.'s competitors?
- Travere Therapeutics, Inc.'s key competitors include Vertex Pharmaceuticals, Vera Therapeutics, Inc. Class A Common Stock, Jade Biosciences, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Travere Therapeutics, Inc. partner with?
- Travere Therapeutics, Inc.'s notable partners include U.S. Food and Drug Administration.
- Where is Travere Therapeutics, Inc. headquartered?
- Travere Therapeutics, Inc. is headquartered in United States of America and employs approximately 380 people. It has been publicly traded since 2003.
